Category: Investment, Biotech, Pharma

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) to Present at the Bio Investor Forum

Visit this company: www.biosantepharma.com

LINCOLNSHIRE, Ill. - September 30, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Bio Investor Forum to be held on October 5-6, 2009 at the Palace Hotel in San Francisco, California.

Stephen M. Simes, BioSante’s president & chief executive officer, will speak on October 5 at 4:30 pm local time. Mr. Simes will provide a status update on BioSante’s lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.

Contact:

BioSante Pharmaceuticals

For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com

or

For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news is paid for and /or published as information only for our readers.

Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

TOP